Skip to content

US · ORMP · BIOTECHNOLOGY

Oramed Pharmaceuticals Inc. (ORMP) intrinsic value and stock valuation

$3.57as of 2026-11-21 · Mkt cap 175.98M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Oramed Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values ORMP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORMP’s statements →

Oramed Pharmaceuticals Inc. Graham Number

Graham Number: $12.96d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10036 oramed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2M-5.9% 5y CAGRd
20112025
Net income
$64.1M
20112025
Free cash flow
-$-11.08M
20112025
Total equity
$199.7M+43.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2M$0.00$1.34M$2.7M$2.7M
Operating income-$-15.09M-$-12.78M-$-15.77M-$-40.6M-$-24.22M
Net income$64.1M-$-19.1M$5.53M-$-37.76M-$-22.24M
EPSd$1.51M-$-467.79K$136.3K-$-968.21K-$-781.17K
Operating cash flow-$-9.14M-$-8.41M-$-10.29M-$-28.7M-$-21.18M
Capital expenditure-$-1.93M-$-20K-$-250K-$-500K-$-370K
Free cash flow-$-11.08M-$-8.43M-$-10.55M-$-29.2M-$-21.56M
Total assets$230.9M$155.3M$220.6M$161.6M$128M
Total debt$820K$370K$51.6M$890K$530K
Net debt-$-45.12M-$-54.05M$42.6M-$-39.57M-$-76.71M
Total equity$199.7M$145.4M$162.9M$151.2M$116.5M
Cash and short-term investments$125.9M$141.9M$162.1M$155.7M$94.1M
Income statement
20252024202320222021
Revenue$2M$0.00$1.34M$2.7M$2.7M
Cost of revenue$1.99M$190K$0.00$0.00$0.00
Gross profit$10K-$-190K$1.34M$2.7M$2.7M
Research and development expenses$6.38M$6.32M$8.97M$27.6M$21M
Selling, general and administrative expenses$8.72M$6.46M$8.14M$15.7M$5.94M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$15.1M$12.8M$17.1M$43.3M$26.9M
Cost and expenses$17.1M$12.8M$17.1M$43.3M$26.9M
Interest income$2.37M$0.00$8.03M$3.57M$350K
Interest expense$0.00$850K$3.58M$0.00$10K
Depreciation and amortization$120K$190K$200K$3.62M$80K
Ebitda$75.4M-$-14.87M$7.32M-$-36.98M-$-25.04M
Operating income-$-15.09M-$-12.78M-$-15.77M-$-40.6M-$-24.22M
Total other income/expenses, net$90.4M-$-3.14M$20.9M$2.93M$890K
Income before tax$75.3M-$-15.92M$5.09M-$-37.66M-$-22.99M
Income tax expense$11.3M$3.18M$0.00$100K-$-2.88M
Net income$64.1M-$-19.1M$5.53M-$-37.76M-$-22.24M
Weighted average shares outstanding$41.4M$40.8M$40.3M$39M$28.5M
Weighted average diluted shares outstanding$42.4M$40.8M$40.6M$39M$28.5M
Balance sheet
20252024202320222021
Cash and short-term investments$125.9M$141.9M$162.1M$155.7M$94.1M
Net receivables$4.64M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$133.3M$143.2M$162.6M$157.1M$95.3M
Property, plant and equipment, net$1.34M$1.11M$1.57M$1.81M$930K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$93.7M$10.9M$56.4M$2.7M$6.69M
Total non-current assets$97.6M$12.1M$58M$4.53M$32.7M
Total assets$230.9M$155.3M$220.6M$161.6M$128M
Accounts payable$440K$790K$550K$2.17M$2.61M
Short-term debt$280K$220K$51.3M$250K$130K
Deferred revenue$1.35M$0.00$0.00$1.34M$2.7M
Total current liabilities$19.1M$5.68M$53.2M$5.75M$6.68M
Long-term debt$540K$160K$340K$650K$400K
Deferred revenue, non-current$3.27M$4M$4M$4M$4.24M
Total non-current liabilities$12M$4.25M$4.44M$4.74M$4.8M
Capital lease obligations$540K$370K$610K$0.00$0.00
Total liabilities$31.1M$9.93M$57.7M$10.5M$11.5M
Common stock$470K$480K$480K$480K$420K
Retained earnings-$-123.44M-$-176.62M-$-157.56M-$-163.08M-$-114.85M
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00$0.00$0.00
Total equity$199.7M$145.4M$162.9M$151.2M$116.5M
Total investments$173.7M$98.4M$209.4M$118M$23.6M
Total debt$820K$370K$51.6M$890K$530K
Net debt-$-45.12M-$-54.05M$42.6M-$-39.57M-$-76.71M
Cash flow statement
20252024202320222021
Net income$64M-$-19.06M$5.53M-$-36.56M-$-22.24M
Depreciation and amortization$120K$190K$200K$60K$80K
Stock-based compensation$5.99M$0.00$0.00$0.00$0.00
Change in working capital-$-1.91M$3.2M-$-2.7M-$-940K-$-1.31M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.13M$3.52M-$-2.23M-$-380K$2.06M
Net cash provided by operating activities-$-9.14M-$-8.41M-$-10.29M-$-28.7M-$-21.18M
Investments in property, plant and equipment-$-1.93M-$-20K-$-250K-$-500K-$-380K
Acquisitions, net-$-7.25M$0.00$0.00$20K$1.5M
Net cash used for investing activities$5.44M$105.8M-$-73.04M$30.2M-$-22.26M
Common stock issued$0.00$0.00$2.43M$11.6M$101.4M
Common stock repurchased-$-4.74M-$-2.48M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-4.74M-$-52.04M$52M$11.6M$101.4M
Net change in cash-$-8.47M$45.4M-$-31.41M-$-36.78M$58M
Cash at end of period$46M$54.4M$9.05M$40.5M$77.3M
Operating cash flow-$-9.14M-$-8.41M-$-10.29M-$-28.7M-$-21.18M
Capital expenditure-$-1.93M-$-20K-$-250K-$-500K-$-370K
Free cash flow-$-11.08M-$-8.43M-$-10.55M-$-29.2M-$-21.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Oramed Pharmaceuticals Inc.

        Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

        CEO
        Nadav Kidron
        Employees
        13
        Beta
        1.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Oramed Pharmaceuticals Inc. (ORMP)?

        InvestorsCraft does not currently publish an intrinsic value for ORMP. How the IC value is calculated.

        Is ORMP undervalued?

        InvestorsCraft does not publish an undervaluation signal for ORMP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.